中国药物经济学2025，Vol.20Issue(4)：35-39,43,6.DOI:10.12010/j.issn.1673-5846.2025.04.006
氢溴酸樟柳碱注射液治疗急性缺血性脑卒中的预算影响分析
Budget Impact Analysis of Anisodine Hydrobromide Injection in the Treatment of Acute Ischemic Stroke
摘要
Abstract
Objective To calculate the overall budget impact of the Anisodine Hydrobromide Injection introduced into the national medical insurance,and provide evidence for decision-makers.Methods From the perspective of medical insurance payers,establish a budget impact analysis model with the research period of 2025 to 2029.The model is aimed at newly diagnosed acute ischemic stroke patients and compares the impact of Anisodine Hydrobromide Injection on the budget expenditure of medical insurance funds under two scenarios:not entering medical insurance and entering medical insurance.Results If Anisodine Hydrobromide Injection is included in the national medical insurance drug catalogue,according to the price reduction and share changes of drugs after being included in the medical insurance catalogue in the past,it is expected that from 2025 to 2029,the medical insurance fund expenditure may increase by 62 million yuan,157 million yuan,91 million yuan,85 million yuan and 79 million yuan respectively.The average annual medical insurance expenditure is more than 95 million yuan,and the increased medical insurance expenditure in each year accounts for 1.32%,3.27%,1.91%,1.78%and 1.67%of the estimated medical insurance related drug expenditure in the year,respectively.Conclusion After Anisodine Hydrobromide Injection into the medical insurance catalog,the number of patients receiving treatment increased,and the expenditure of the medical insurance fund also increased accordingly.However,the impact on the overall expenditure of the medical insurance fund was relatively small.关键词
氢溴酸樟柳碱/急性缺血性脑卒中/预算影响分析Key words
Anisodine Hydrobromide/Acute ischemic stroke/Budget impact analysis分类
临床医学引用本文复制引用
任晓明,王丽霞,万峰..氢溴酸樟柳碱注射液治疗急性缺血性脑卒中的预算影响分析[J].中国药物经济学,2025,20(4):35-39,43,6.基金项目
国家卫健委委托项目(0300000006) （0300000006）
